Local Tech Wire

RESEARCH TRIANGLE PARK, N.C. – Two GlaxoSmithKline (NYSE: GSK) executives have been "ordered” to resign from a non-profit venture that they helped launch since it was selling over the Internet a supplement related to resveratrol.

The executives worked for Massachusetts-based Sirtris, which GSK had acquired for $720 million in 2008 for its resveratrol development. Resveratrol is an anti-aging supplement.

Cristoph Westphal, former CEO at Sirtris, and Michelle Dipp were told to step down from , according to The Street. The two direct resveratrol development at GSK, The Street noted.

“Unbeknownst to Glaxo, the two executives were also moonlighting as purveyors of their own custom-made dietary formulation of resveratrol,” The Street said.

For details,

GSK maintains its U.S. headquarters in RTP.

Get the latest news alerts: at Twitter.